Clinical Trials
11 trialsNCT07183189 2026-04-14
A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3 Recruiting
NCT07130916 2025-08-19
A Study of Aumolertinib in European Participants With Non-Small Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT06417008 2025-08-01
A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer
Hansoh BioMedical R&D Company
Phase 2/3 Recruiting
NCT06951464 2025-07-23
A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC
Sichuan University
Phase 2 Recruiting
NCT06947811 2025-06-04
APEAK
Sun Yat-sen University
Phase 1/2 Recruiting
NCT04423185 2025-02-11
PLATFORM Study of Precision Medicine for Rare Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06102928 2023-10-26
A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation
Kunming Medical University
Phase NA Recruiting
NCT06043973 2023-09-21
Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance
Qianfoshan Hospital
Phase 3 Recruiting
NCT05800223 2023-04-05
Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer
Shanghai Cancer Hospital, China
Phase 3 Recruiting
NCT05768490 2023-03-14
Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases
Sun Yat-sen University
Phase 3 Recruiting
NCT04951635 2022-06-16
A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 3 Recruiting